This site is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

BIO-Europe
Save the date!
November 6–8, 2023Munich, Germany

Faical Miyara
Head of Global Partnering, Oncology at Ipsen

Profile

Faiçal Miyara is an innovative leader with over 16 years’ experience in the pharmaceutical industry, including 9 years of extensive hands-on experience in US corporate and business development with a proven record in negotiating, generating NBOs, and finalizing business deals for in-licensing, out-licensing programs, and M&A. Faiçal served as head of External Research and Business Development at Kadmon Corporation. In his role, Faiçal managed and directed global scouting, evaluation, and negotiation of licensing deals, covering the entire spectrum from early research stage to late-clinical development and marketed product opportunities, both in biologics and small molecules. He played a crucial role in the approval of Belumsudil [Rezurock™] and in the M&A process that led to Kadmon acquisition by Sanofi.

Prior to Kadmon, Faiçal spent 5 years at Pfizer, Inc. where he co-initiated and co-developed one of its Therapeutic Innovation centers (CTI) in NYC where he held a series of senior R&D roles of increasing responsibility. Prior to joining Pfizer, he spent 5 years at ImClone Systems/Eli Lilly where he contributed to the research, optimization, and development of numerous FDA approved biologics to treat cancer including Cetuximab [Erbitux®], Ramucirumab [CYRAMZA®], Necitumumab [Portrazza™] and Olaratumab [Lartruvo®].

Faiçal has a Ph.D. in reproductive, molecular and cell biology from the University Pierre et Marie Currie (Paris VI, France), and a Master's/ Engineer degree of Medical Biology from the Faculty of Medicine Joseph Fourier, Grenoble, France. Faiçal has authored multiple patents, book chapters, and papers in peer-reviewed science journals.

Agenda Sessions

  • Global dealmaking in a global indication: oncology partnering in 2022

    09:00